Focusing on the Frontier of Fertility Preservation, Building Hope for Life Together — The 2026 Annual Academic Conference on Eugenics and Healthy Childbirth of Shenzhen Association of Traditional Chinese Medicine Concludes Successfully
Release time:
2026-08-21
On August 15, 2026, the 2026 Annual Academic Conference of the Eugenics and Healthy Childbirth Professional Committee of Shenzhen Association of Traditional Chinese Medicine, along with the 2026 Academic Conference of the "Three Famous Projects" — the Integrated Traditional Chinese and Western Medicine Gynecology Team led by Professor You Zhaoling from the First Affiliated Hospital of Hunan University of Chinese Medicine, was successfully convened. The conference was hosted by Shenzhen Association of Traditional Chinese Medicine and Shenzhen Longgang District Medical Association, and organized by Beijing University of Chinese Medicine Shenzhen Hospital (Longgang), among others. Focusing on clinical hot topics such as female fertility preservation and conservation, chronic gynecological disease management, diagnosis and treatment of infertility, integrated TCM-Western medicine assisted reproduction, and eugenics, the conference brought together experts in gynecology, reproductive medicine, and TCM from both within and outside the province to discuss disciplinary development and share clinical experience.
Balancing Academic Frontiers with Clinical Practice: Exploring New Pathways for Fertility Preservation
The conference featured parallel sessions in two venues, focusing respectively on fertility preservation and conservation, and the management of chronic gynecological diseases in relation to fertility protection. Experts from the First Affiliated Hospital of Hunan University of Chinese Medicine, the Affiliated Hospital of Jiangxi University of Chinese Medicine, Qingdao Municipal Hospital, and Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) conducted special seminars on hot topics including integrated TCM-Western medicine diagnosis and treatment of RPOC (Retained Products of Conception), TCM protocols for improving endometrial receptivity after hysteroscopic surgery, clinical experience with intrauterine perfusion in embryo transfer, integrated TCM-Western medicine strategies for varicocele-related infertility, comprehensive TCM management and treatment strategies for tubal infertility, clinical application of PFC (Preimplantation Fetal Chromosome screening/preparation) technology and ovarian tissue cryopreservation and activation technology, and analysis of paternal factors in recurrent miscarriage.
Yinfeng's In-Depth Participation: Ovarian Dual Activation Technology Becomes a Highlight
Liu Zhicheng, Vice President of Shandong Yinfeng Life Science Research Institute (hereinafter referred to as "Yinfeng Life Science Institute"), was invited to attend the conference. During the meeting, experts from Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) delivered a special presentation on a key collaborative project with Yinfeng Life Science Institute — the principles and clinical applications of ovarian tissue cryopreservation and activation technology. Dedicated to solving the core challenges of female fertility, this technology integrates cutting-edge cryogenic technology with biomedical clinical practice, providing a brand-new solution for fertility preservation in patients with infertility, diminished ovarian reserve (DOR), and reproductive-age cancer patients. It fully demonstrates Yinfeng's level of scientific exploration and clinical translation in the fields of life extension and reproductive health.
Exclusive Member Benefits: Touching the Frontiers of Scientific Research Up Close
Meanwhile, the conference specially secured valuable participation slots for members of the Yinfeng Life Extension Program, establishing an exclusive channel for members to learn about the program's research progress. Members attended the event in person, engaging in face-to-face exchanges with top domestic experts in gynecology and reproductive medicine, obtaining the latest research updates on fertility cryopreservation at the first opportunity, and personally witnessing the solid strides Yinfeng has made in the field of life science research.
Inheriting the past to reach far, upholding the right and innovating. In the future, Yinfeng Life Science Institute will be driven by scientific research innovation, continue to join hands with authoritative medical institutions, promote scientific breakthroughs and clinical translation in the field of reproductive health, and let the light of hope for life extension illuminate more families.
Previous article
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
